Hedgehog inhibitors exert anti-proliferation effects and synergistically interact with trastuzumab in HER2-positive gastric cancer models
DOI:
https://doi.org/10.2340/1651-226X.2025.42219Keywords:
Gastric cancer, HER2 receptor, Trastuzumab, Hedgehog signaling, AKT/mTORAbstract
Background: Gastric cancer (GC) remains a significant health concern with limited therapeutic options. While trastuzumab, a Human Epidermal Growth Factor Receptor 2 (HER2)-targeting antibody, has shown efficacy in HER2-positive GC, its therapeutic response is moderate. Hedgehog (Hh) signalling plays a critical role in the progression of GC.
Methods: We evaluated the sensitivity of various GC cell lines to trastuzumab. The HER2-positive HGC-27 cell line was identified as the most sensitive. In addition, the effects of two Hedgehog inhibitors, vismodegib and cyclopamine, were assessed on cell growth by monitoring SMO expression. Both in vitro and in vivo assays were conducted to explore the combination of Hh inhibitors and trastuzumab.
Results: Both vismodegib and cyclopamine exerted anti-proliferative effects, and synergistically enhanced the anti-tumour activity of trastuzumab in HER2-positive GC models. Mechanistically, Hh inhibitors inhibited the AKT/mTOR signalling pathway through Smoothened (SMO) depletion, contributing to their anti-growth effects.
Interpretation: This study highlights the potential of combining Hh inhibitors with trastuzumab as a therapeutic strategy for HER2-positive GC by targeting the AKT/mTOR pathway.
Downloads
References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2020;70(4):313.
https://doi.org/10.3322/caac.21609 DOI: https://doi.org/10.3322/caac.21609
Yusefi AR, Bagheri Lankarani K, Bastani P, Radinmanesh M, Kavosi Z. Risk Factors for Gastric Cancer: A Systematic Review. Asian Pac J Cancer Prev. 2018;19(3):591–603.
Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies. Int J Mol Sci. 2020;21(11).
https://doi.org/10.3390/ijms21114012 DOI: https://doi.org/10.3390/ijms21114012
Morgan E, Arnold M, Camargo MC, Gini A, Kunzmann AT, Matsuda T, et al. The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: A population-based modelling study. EClinicalMedicine. 2022;47:101404.
https://doi.org/10.1016/j.eclinm.2022.101404 DOI: https://doi.org/10.1016/j.eclinm.2022.101404
Cunningham, D., Allum, W. H., Stenning, S. P., Thompson, J. N., Van de Velde, C. J., Nicolson, M., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.
https://doi.org/10.1056/NEJMoa055531 DOI: https://doi.org/10.1056/NEJMoa055531
Kuhnle PJ, Israel KF, Menges M. Real-life data on improvement of survival after perioperative chemotherapy versus surgery alone on resectable adenocarcinoma of the stomach - a single-cen- ter study. Z Gastroenterol. 2019;57(5):606-610.
https://doi.org/10.1055/a-0841-3513 DOI: https://doi.org/10.1055/a-0841-3513
Mayer RJ, Venook AP, Schilsky RL. Progress against GI cancer during the American Society of Clinical Oncology’s first 50 years. J Clin Oncol. 2014;32(15):1521–1530.
https://doi.org/10.1200/JCO.2014.55.4121 DOI: https://doi.org/10.1200/JCO.2014.55.4121
Ye P, Wang Y, Li R, Chen W, Wan L, Cai P. The HER family as ther- apeutic targets in colorectal cancer. Crit Rev Oncol Hematol. 2022;174:103681.
https://doi.org/10.1016/j.critrevonc.2022.103681 https://doi.org/10.1016/j.critrevonc.2022.103681 DOI: https://doi.org/10.1016/j.critrevonc.2022.103681
Kalmuk J, Rinder D, Heltzel C, Lockhart AC. An overview of the preclinical discovery and development of trastuzumab deruxte- can: a novel gastric cancer therapeutic. Expert Opin Drug Discov. 2022;17(5):427-436.
https://doi.org/10.1080/17460441.2022.2050692 DOI: https://doi.org/10.1080/17460441.2022.2050692
Yu X, Ji X, Su C. HER2-altered non-small cell lung cancer: biology, clinicopathologic features, and emerging therapies. Front Oncol. 2022;12:860313.
https://doi.org/10.3389/fonc.2022.860313 DOI: https://doi.org/10.3389/fonc.2022.860313
Begnami MD, Fukuda E, Fregnani JH, Nonogaki S, Montagnini AL, da Costa WL, Jr., et al. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol. 2011;29(22):3030–3036.
https://doi.org/10.1200/JCO.2010.33.6313 DOI: https://doi.org/10.1200/JCO.2010.33.6313
Bang K, Cheon J, Park YS, Kim HD, Ryu MH, Park Y, et al. Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab. Gastric Cancer. 2022;25(4):794–803.
https://doi.org/10.1007/s10120-022-01298-6 DOI: https://doi.org/10.1007/s10120-022-01298-6
Fukai S, Nakajima S, Saito M, Saito K, Kase K, Nakano H, et al. Down-regulation of stimulator of interferon genes (STING) expression and CD8(+) T-cell infiltration depending on HER2 heterogeneity in HER2-positive gastric cancer. Gastric Cancer. 2023;26(6):878–890.
https://doi.org/10.1007/s10120-023-01417-x DOI: https://doi.org/10.1007/s10120-023-01417-x
Tsujio G, Maruo K, Yamamoto Y, Sera T, Sugimoto A, Kasashima H, et al. Significance of tumor heterogeneity of p-Smad2 and c-Met in HER2-positive gastric carcinoma with lymph node metastasis. BMC Cancer. 2022;22(1):598.
https://doi.org/10.1186/s12885-022-09681-3 DOI: https://doi.org/10.1186/s12885-022-09681-3
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–697.
https://doi.org/10.1016/S0140-6736(10)61121-X DOI: https://doi.org/10.1016/S0140-6736(10)61121-X
Van Cutsem E, Bang YJ, Feng-Yi F, Xu JM, Lee KW, Jiao SC, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18(3):476–484.
https://doi.org/10.1007/s10120-014-0402-y DOI: https://doi.org/10.1007/s10120-014-0402-y
Janjigian YY, Kawazoe A, Yanez P, Li N, Lonardi S, Kolesnik O, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600(7890):727–730.
https://doi.org/10.1038/s41586-021-04161-3 DOI: https://doi.org/10.1038/s41586-021-04161-3
Roviello G, Catalano M, Iannone LF, Marano L, Brugia M, Rossi G, Aprile G, et al. Current status and future perspectives in HER2 positive advanced gastric cancer. Clin Transl Oncol. 2022;24(6):981–996.
https://doi.org/10.1007/s12094-021-02760-0 DOI: https://doi.org/10.1007/s12094-021-02760-0
Beachy PA, Hymowitz SG, Lazarus RA, Leahy DJ, Siebold C. Interactions between Hedgehog proteins and their binding partners come into view. Genes Dev. 2010;24(18):2001–2012.
https://doi.org/10.1101/gad.1951710 DOI: https://doi.org/10.1101/gad.1951710
Pietrobono S, Gagliardi S, Stecca B. Non-canonical Hedgehog Signaling Pathway in Cancer: Activation of GLI Transcription Factors Beyond Smoothened. Front Genet. 2019;10:556.
https://doi.org/10.3389/fgene.2019.00556 DOI: https://doi.org/10.3389/fgene.2019.00556
Li B, Huang W, Cao N, Lou G. Forkhead-box R2 promotes metas- tasis and growth by stimulating angiogenesis and activating hedgehog signaling pathway in ovarian cancer. J Cell Biochem. 2018;119(9):7780–7789.
https://doi.org/10.1002/jcb.27148 DOI: https://doi.org/10.1002/jcb.27148
Ohta M, Tateishi K, Kanai F, Watabe H, Kondo S, Guleng B, et al. p53-Independent negative regu-lation of p21/cyclin-dependent kinase-interacting protein 1 by the sonic hedgehog-glioma-associated oncogene 1 pathway in gastric carcinoma cells. Cancer Res. 2005;65(23):10822–10829.
https://doi.org/10.1158/0008-5472.CAN-05-0777 DOI: https://doi.org/10.1158/0008-5472.CAN-05-0777
Lu Y, Zhang B, Wang B, Wu D, Wang C, Gao Y, et al. MiR-144-3p inhibits gastric cancer progression and stemness via directly targeting GLI2 involved in hedgehog pathway. J Transl Med. 2021;19(1):432.
https://doi.org/10.1186/s12967-021-03093-w DOI: https://doi.org/10.1186/s12967-021-03093-w
Xin L, Liu L, Liu C, Zhou LQ, Zhou Q, Yuan YW, et al. DNA-methylation-mediated silencing of miR-7-5p promotes gastric cancer stem cell invasion via increasing Smo and Hes1. J Cell Physiol. 2020;235(3):2643–2654.
https://doi.org/10.1002/jcp.29168 DOI: https://doi.org/10.1002/jcp.29168
Curragh DS, Huilgol SC, Selva D. Neoadjuvant vismodegib in the management of locally advanced periocular basal cell carcinoma. Eye (Lond). 2021;35(10):2740–2745.
https://doi.org/10.1038/s41433-020-01291-2 DOI: https://doi.org/10.1038/s41433-020-01291-2
Na YJ, Lee DH, Kim JL, Kim BR, Park SH, Jo MJ, et al. Cyclopamine sensitizes TRAIL-resistant gastric cancer cells to TRAIL-induced apoptosis via endoplasmic reticulum stress-mediated increase of death receptor 5 and survivin degradation. Int J Biochem Cell Biol. 2017;89:147–156.
https://doi.org/10.1016/j.biocel.2017.06.010 DOI: https://doi.org/10.1016/j.biocel.2017.06.010
Feldmann G, Dhara S, Fendrich V, Bedja D, Beaty R, Mullendore M, et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res. 2007;67(5): 2187–2196.
https://doi.org/10.1158/0008-5472.CAN-06-3281 DOI: https://doi.org/10.1158/0008-5472.CAN-06-3281
Er I, Boz Er AB. Hedgehog Pathway Is a Regulator of Stemness in HER2-Positive Trastuzumab-Resistant Breast Cancer. Int J Mol Sci. 2024;25(22).
https://doi.org/10.3390/ijms252212102 DOI: https://doi.org/10.3390/ijms252212102
Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9(7):671–675.
https://doi.org/10.1038/nmeth.2089 DOI: https://doi.org/10.1038/nmeth.2089
Chen Y, Peng C, Chen J, Chen D, Yang B, He B, et al. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1. Mol Cancer. 2019;18(1):127.
https://doi.org/10.1186/s12943-019-1053-8 DOI: https://doi.org/10.1186/s12943-019-1053-8
Wen P, Wang H, Li Y, Sui X, Hou Z, Guo X, et al. MICALL2 as a substrate of ubiquitinase TRIM21 regulates tumorigenesis of colorectal cancer. Cell Commun Signal. 2022;20(1):170.
https://doi.org/10.1186/s12964-022-00984-3 DOI: https://doi.org/10.1186/s12964-022-00984-3
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–408.
https://doi.org/10.1006/meth.2001.1262 DOI: https://doi.org/10.1006/meth.2001.1262
Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621–681.
https://doi.org/10.1124/pr.58.3.10 DOI: https://doi.org/10.1124/pr.58.3.10
Wan J, Zhou J, Zhao H, Wang M, Wei Z, Gao H, et al. Sonic hedgehog pathway contributes to gastric cancer cell growth and proliferation. Biores Open Access. 2014;3(2):53–59.
https://doi.org/10.1089/biores.2014.0001 DOI: https://doi.org/10.1089/biores.2014.0001
Berman DM, Karhadkar SS, Maitra A, Montes De Oca R, Gerstenblith MR, Briggs K, et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature. 2003;425(6960):846–851.
https://doi.org/10.1038/nature01972 DOI: https://doi.org/10.1038/nature01972
Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst. 1994;86(20):1517–1524.
https://doi.org/10.1093/jnci/86.20.1517 DOI: https://doi.org/10.1093/jnci/86.20.1517
Mukaka MM. Statistics corner: A guide to appropriate use of correlation coefficient in medical research. Malawi Med J. 2012;24(3):69–71.
Zhou J, Zhu G, Huang J, Li L, Du Y, Gao Y, et al. Non-canonical GLI1/2 activation by PI3K/AKT signaling in renal cell carcinoma: A novel potential therapeutic target. Cancer Lett. 2016;370(2):313–23.
https://doi.org/10.1016/j.canlet.2015.11.006 DOI: https://doi.org/10.1016/j.canlet.2015.11.006
Sharma N, Nanta R, Sharma J, Gunewardena S, Singh KP, Shankar S, et al. PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth. Oncotarget. 2015;6(31):32039–32060.
https://doi.org/10.18632/oncotarget.5055 DOI: https://doi.org/10.18632/oncotarget.5055
Lazar DC, Taban S, Cornianu M, Faur A, Goldis A. New advances in targeted gastric cancer treatment. World J Gastroenterol. 2016;22(30):6776–6799.
https://doi.org/10.3748/wjg.v22.i30.6776 DOI: https://doi.org/10.3748/wjg.v22.i30.6776
Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab Deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419–2430.
https://doi.org/10.1056/NEJMoa2004413 DOI: https://doi.org/10.1056/NEJMoa2004413
Siena S, Marsoni S, Sartore-Bianchi A. Breaking barriers in HER2+ cancers. Cancer Cell. 2020;38(3):317–319.
https://doi.org/10.1016/j.ccell.2020.07.012 DOI: https://doi.org/10.1016/j.ccell.2020.07.012
Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8:CD004064.
https://doi.org/10.1002/14651858.CD004064.pub4 DOI: https://doi.org/10.1002/14651858.CD004064.pub4
Shi W, Zhang G, Ma Z, Li L, Liu M, Qin L, et al. Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer. Nat Commun. 2021;12(1):2812.
https://doi.org/10.1038/s41467-021-23053-8 DOI: https://doi.org/10.1038/s41467-021-23053-8
Sato Y, Okamoto K, Kida Y, Mitsui Y, Kawano Y, Sogabe M, et al. Overview of Chemotherapy for Gastric Cancer. J Clin Med. 2023;12(4).
https://doi.org/10.3390/jcm12041336 DOI: https://doi.org/10.3390/jcm12041336
Doheny D, Sirkisoon S, Carpenter RL, Aguayo NR, Regua AT, Anguelov M, et al. Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis. Oncogene. 2020;39(42):6589–6605.
https://doi.org/10.1038/s41388-020-01454-1 DOI: https://doi.org/10.1038/s41388-020-01454-1
Rong L, Li Z, Leng X, Li H, Ma Y, Chen Y, et al. Salidroside induces apoptosis and protective autophagy in human gastric cancer AGS cells through the PI3K/Akt/mTOR pathway. Biomed Pharmacother. 2020;122:109726.
https://doi.org/10.1016/j.biopha.2019.109726 DOI: https://doi.org/10.1016/j.biopha.2019.109726
Fattahi S, Amjadi-Moheb F, Tabaripour R, Ashrafi GH, Akhavan-Niaki H. PI3K/AKT/mTOR signaling in gastric cancer: Epigenetics and beyond. Life Sci. 2020;262:118513.
https://doi.org/10.1016/j.lfs.2020.118513 DOI: https://doi.org/10.1016/j.lfs.2020.118513
Xiao M, Lin C, Yang Z, Tian S, Huang Y, Fu J. Compound TDB (Tricyclic decyl benzoxazole) induces autophagy-dependent apoptosis in the gastric cancer cell line MGC-803 by regulating PI3K/AKT/mTOR. Am J Transl Res. 2021;13(1):73–87.
Wu YJ, Lin SH, Din ZH, Su JH, Liu CI. Sinulariolide inhibits gastric can- cer cell migration and invasion through downregulation of the EMT process and suppression of FAK/PI3K/AKT/mTOR and MAPKs sig- naling pathways. Mar Drugs. 2019;17(12).
https://doi.org/10.3390/md17120668 DOI: https://doi.org/10.3390/md17120668
Kim MY, Kruger AJ, Jeong JY, et al. Combination therapy with a PI3K/ mTOR dual inhibitor and chloroquine enhances synergistic apoptotic cell death in Epstein-Barr virus-infected gastric cancer cells. Mol Cells. 2019;42(6):448–459.
https://doi.org/10.14348/molcells.2019.2395 DOI: https://doi.org/10.14348/molcells.2019.2395
Koh V, Chakrabarti J, Torvund M, Steele N, Hawkins JA, Ito Y, et al. Hedgehog transcriptional effector GLI mediates mTOR-Induced PD-L1 expression in gastric cancer organoids. Cancer Lett. 2021;518:59–71.
https://doi.org/10.1016/j.canlet.2021.06.007 DOI: https://doi.org/10.1016/j.canlet.2021.06.007
Po A, Silvano M, Miele E, Capalbo C, Eramo A, Salvati V, et al. Noncanonical GLI1 signaling promotes stemness features and in vivo growth in lung adenocarcinoma. Oncogene. 2017;36(32):4641–4652.
https://doi.org/10.1038/onc.2017.91 DOI: https://doi.org/10.1038/onc.2017.91
Rahman MM, Hazan A, Selway JL, Herath DS, Harwood CA, Pirzado MS, et al. A Novel Mechanism for Activation of GLI1 by Nuclear SMO That Escapes Anti-SMO Inhibitors. Cancer Res. 2018;78(10):2577–2588.
https://doi.org/10.1158/0008-5472.CAN-17-2897 DOI: https://doi.org/10.1158/0008-5472.CAN-17-2897
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Zixin Yang, Ren Niu, Jinzhu Han, Jie Guo, Yingqian Lv
This work is licensed under a Creative Commons Attribution 4.0 International License.
